Conatus (CNAT), Galmed (GLMD), Intercept (ICPT) Could Be Given Similar Considerations for their Assets - FBR

September 20, 2016 10:54 AM EDT
Get Alerts AGN Hot Sheet
Price: $214.34 -0.11%

Rating Summary:
    18 Buy, 13 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade AGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

FBR Capital analyst Vernon Bernardino weighed in on the NASH space after Allergan (NASDAQ: AGN) agreed to acquire Tobira Therapeutics (NASDAQ: TBRA) for a 500% up-front payment and up to $49.84 per share in Contingent Value Rights (CVRs)

Bernardino commented, "While the acquisition premium (500% premium over yesterday's closing price of $4.74/share for TBRA) is outsized even in biotech terms, we think the drug development landscape in NASH, which has been estimated to have $40 billion in market potential, has no approved drugs and is comprised of less than a half dozen drug candidates in the Phase II stage of development. We think companies under our coverage that could be given similar consideration include Conatus Pharmaceuticals (NASDAQ: CNAT), and Galmed Pharmaceuticals (NASDAQ: GLMD), as well as Intercept Pharmaceuticals (NASDAQ: ICPT), which along with Genfit , are the only ones in the Phase III stage of development."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Rumors

Related Entities

Definitive Agreement

Add Your Comment